Attention-deficit drugs boost Shire

■ Pharmaceutical firm Shire posted a 20 per cent rise in first-quarter earnings yesterday, just beating market expectations, as its drugs to treat hyperactivity lifted its US market share. Shire reported earnings per American Depositary Share of $1.48 in the three months to the end of March, on revenue 21 per cent higher at $1.17bn.